Improving dialysis membranes to better remove harmful toxins from blood
Enhanced renal dialysis membrane performance using lipocalin modified substrates
['FUNDING_SBIR_1'] · HIBAR MICROSCIENCES, LLC · NIH-10691958
This study is looking at ways to make dialysis treatments better for people with kidney failure by using special proteins to help remove harmful toxins from their blood more effectively.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HIBAR MICROSCIENCES, LLC (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10691958 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the performance of dialysis membranes used in treating patients with end-stage renal disease (ESRD). The approach involves modifying membranes with Lipocalin proteins to improve the clearance of harmful protein-bound uremic toxins from the blood, which are often not effectively removed by current dialysis methods. By utilizing advanced techniques, the study aims to demonstrate increased extraction rates of these toxins, potentially leading to better health outcomes for patients undergoing dialysis.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are undergoing hemodialysis due to end-stage renal disease.
Not a fit: Patients who do not require dialysis or have functioning kidneys will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective dialysis treatments, improving the health and quality of life for patients with chronic kidney disease.
How similar studies have performed: Previous research has shown promise in enhancing dialysis technologies, but this specific approach using Lipocalin-modified membranes is novel and has not been extensively tested.
Where this research is happening
ATLANTA, UNITED STATES
- HIBAR MICROSCIENCES, LLC — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TUMLIN, JAMES A — HIBAR MICROSCIENCES, LLC
- Study coordinator: TUMLIN, JAMES A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.